{"drugs":["Belviq","Lorcaserin Hydrochloride"],"mono":{"0":{"id":"930230-s-0","title":"Generic Names","mono":"Lorcaserin Hydrochloride"},"1":{"id":"930230-s-1","title":"Dosing and Indications","sub":[{"id":"930230-s-1-4","title":"Adult Dosing","mono":"<b>Obesity:<\/b> 10 mg ORALLY twice daily; discontinue at week 12 if 5% weight loss has not been achieved; MAX 20 mg\/day "},{"id":"930230-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients; use not recommended "},{"id":"930230-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, mild:<\/b> no adjustment necessary<\/li><li><b>renal impairment, severe or ESRD:<\/b> use not recommended<\/li><li><b>hepatic impairment, mild to moderate:<\/b> no adjustment necessary<\/li><\/ul>"},{"id":"930230-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Obesity<br\/>"}]},"3":{"id":"930230-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930230-s-3-9","title":"Contraindications","mono":"pregnancy; weight loss may cause fetal harm <br\/>"},{"id":"930230-s-3-10","title":"Precautions","mono":"<ul><li>bradycardia; decreased heart rate has been reported<\/li><li>concomitant use with serotonergic and dopaminergic drugs that are potent 5-HT(2B) receptor agonists and that are known to increase the risk for cardiac valvulopathy (eg, cabergoline) is not recommended<\/li><li>congestive heart failure; potentially increased risk of regurgitant cardiac valvular disease<\/li><li>diabetes mellitus treated with insulin or insulin secretagogues (eg, sulfonylureas); risk of hypoglycemia; dose adjustment of antidiabetic medications may be necessary<\/li><li>heart block greater than first degree; decreased heart rate has been reported<\/li><li>hematologic changes, including decreased WBC (eg, leukopenia, lymphopenia, neutropenia, and decreased white cell count) and decreased RBC (eg, anemia and decreases in hemoglobin and hematocrit), have been reported; monitoring recommended<\/li><li>hepatic impairment, severe; use with caution<\/li><li>priapism may occur; increased risk with predisposing conditions (eg, sickle cell anemia, multiple myeloma, or leukemia) or anatomical deformation of the penis; immediate discontinuation required<\/li><li>prolactin level elevations have been reported<\/li><li>pulmonary hypertension may occur<\/li><li>renal impairment, moderate; use with caution<\/li><li>renal impairment, severe, or end-stage renal disease; use not recommended<\/li><li>serotonin syndrome, including cases that are life-threatening or that resemble neuroleptic malignant syndrome, may occur; increased risk with concomitant serotonergic or antidopaminergic medications or drugs that impair serotonin metabolism; discontinue use if symptoms occur<\/li><li>suicidal ideation and behavior, new-onset or worsening of depression, and unusual changes in mood or behavior may occur; monitoring recommended; discontinue therapy if suicidal thoughts or behaviors develop<\/li><li>valvular heart disease, regurgitant, may occur; drug discontinuation may be required<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930230-s-3-11","title":"Pregnancy Category","mono":"Lorcaserin: X (FDA)<br\/>"},{"id":"930230-s-3-12","title":"Breast Feeding","mono":"Lorcaserin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930230-s-4","title":"Drug Interactions","sub":[{"id":"930230-s-4-13","title":"Contraindicated","mono":"<ul>Thioridazine (theoretical)<\/ul>"},{"id":"930230-s-4-14","title":"Major","mono":"<ul><li>Almotriptan (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Amphetamine (theoretical)<\/li><li>Brompheniramine (theoretical)<\/li><li>Buspirone (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Chlorpheniramine (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Cocaine (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Desvenlafaxine (theoretical)<\/li><li>Dextroamphetamine (theoretical)<\/li><li>Dextromethorphan (established)<\/li><li>Dolasetron (theoretical)<\/li><li>Doxepin (theoretical)<\/li><li>Duloxetine (theoretical)<\/li><li>Eletriptan (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Fenfluramine (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Fluvoxamine (theoretical)<\/li><li>Frovatriptan (theoretical)<\/li><li>Furazolidone (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Hydroxytryptophan (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Iproniazid (theoretical)<\/li><li>Isocarboxazid (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Linezolid (theoretical)<\/li><li>Lithium (theoretical)<\/li><li>Meperidine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Methylene Blue (theoretical)<\/li><li>Milnacipran (theoretical)<\/li><li>Mirtazapine (theoretical)<\/li><li>Naratriptan (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Palonosetron (theoretical)<\/li><li>Paroxetine (theoretical)<\/li><li>Pentazocine (theoretical)<\/li><li>Phenelzine (theoretical)<\/li><li>Procarbazine (theoretical)<\/li><li>Propoxyphene (theoretical)<\/li><li>Rasagiline (theoretical)<\/li><li>Rizatriptan (theoretical)<\/li><li>Selegiline (theoretical)<\/li><li>Sertraline (theoretical)<\/li><li>Sibutramine (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Sumatriptan (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Tranylcypromine (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Tryptophan (theoretical)<\/li><li>Valproic Acid (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><li>Zolmitriptan (theoretical)<\/li><\/ul>"}]},"5":{"id":"930230-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea (8.3% to 9.4%)<\/li><li><b>Neurologic:<\/b>Dizziness (7% to 8.5%), Headache (14.5% to 16.8%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (11.3% to 13%)<\/li><li><b>Other:<\/b>Fatigue (7.2% to 7.4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Heart valve disorder (2.4%)<\/li><li><b>Endocrine metabolic:<\/b>Hypoglycemia (Type 2 diabetic patients, 29.3%)<\/li><li><b>Psychiatric:<\/b>Suicidal thoughts (0.6%)<\/li><li><b>Other:<\/b>Serotonin syndrome<\/li><\/ul>"},"6":{"id":"930230-s-6","title":"Drug Name Info","sub":{"0":{"id":"930230-s-6-17","title":"US Trade Names","mono":"Belviq<br\/>"},"3":{"id":"930230-s-6-20","title":"Regulatory Status","mono":"Schedule IV<br\/>"},"4":{"id":"930230-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930230-s-7","title":"Mechanism Of Action","mono":"Lorcaserin is a selective serotonin 2C (5-HT(2C)) receptor agonist. The exact mechanism of action is not known, but lorcaserin is believed to promote satiety and decrease food intake by activating 5-HT(2C) receptors on anorexigenic pro-opiomelanocortin neurons in the hypothalamus.<br\/>"},"8":{"id":"930230-s-8","title":"Pharmacokinetics","sub":[{"id":"930230-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 1.5 to 2 hours; prolonged to 2.5 hours in elderly subjects<\/li><li>Effect of food: no effect on exposure<\/li><\/ul>"},{"id":"930230-s-8-24","title":"Distribution","mono":"Protein binding: 70% <br\/>"},{"id":"930230-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: extensive<\/li><li>Lorcaserin sulfamate: inactive<\/li><li>N-carbamoyl glucuronide lorcaserin: inactive<\/li><\/ul>"},{"id":"930230-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 2.2%<\/li><li>Renal: 92.3%<\/li><li>Dialyzable: No (hemodialysis)<\/li><\/ul>"},{"id":"930230-s-8-27","title":"Elimination Half Life","mono":"<ul><li>11 hours<\/li><li>Moderate hepatic impairment, 19 hours<\/li><\/ul>"}]},"9":{"id":"930230-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>administer with or without food <br\/>"},"10":{"id":"930230-s-10","title":"Monitoring","mono":"<ul><li>weight loss is indicative of efficacy<\/li><li>blood glucose levels; before starting therapy and during treatment in patients with diabetes mellitus<\/li><li>CBC; periodically during treatment<\/li><li>prolactin levels; when prolactin excess is suspected (eg, galactorrhea, gynecomastia)<\/li><li>response to therapy (weight loss) by week 12<\/li><li>new or worsening depression, suicidal thoughts or behavior, or unusual changes in mood or behavior<\/li><\/ul>"},"11":{"id":"930230-s-11","title":"How Supplied","mono":"<b>Belviq<\/b><br\/>Oral Tablet: 10 MG<br\/>"},"13":{"id":"930230-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness, confusion, and somnolence.<\/li><li>Drug may cause headache, back pain, nausea, dry mouth, constipation, hypoglycemia, cough, and fatigue.<\/li><li>Counsel patient to report signs\/symptoms of serotonin syndrome (agitation, confusion, diaphoresis, hallucinations, hyperreflexia). Concurrent use of serotonergic agents (triptans, tryptophan) may increase risk for serotonin syndrome.<\/li><li>Advise patient to report the emergence or worsening of depression, suicidal thoughts or behavior, and\/or unusual changes in mood or behavior, especially at initiation of therapy or with dose changes.<\/li><li>Advise patient to report signs\/symptoms of valvular heart disease (eg, dyspnea or dependent edema).<\/li><li>Advise patient to discontinue the drug and immediately report an erection that persists longer than 4 hours.<\/li><li>Instruct patient to discontinue use if weight loss of at least 5% of baseline weight has not been achieved after 12 weeks of use.<\/li><\/ul>"}}}